TRABECTEDIN
| Brand name | EVDI |
|---|---|
| Active ingredient | TRABECTEDIN |
| Strength | 1MG/20ML (0.05MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | May 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12303506 | February 2043 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.